IL-3 inhibitors for the treatment of early stage rheumatoid arthritis

• 1. IL-3、IL-33和IL-12P40用于表征由合胞呼吸道病毒引起的呼吸系统感染的用途 [P] . 中国专利： CN108368556B . 2021.06.22
• 2. IL-3、IL-33和IL-12P40用于表征由合胞呼吸道病毒引起的呼吸系统感染的用途 [P] . 中国专利： CN108368556A . 2018-08-03
• 3. IL-3 INHIBITORS IN USE FOR TREATMENT OF RHEUMATOID ARTHRITIS IN AN EARLY STAGE [P] . CA2744960C . 2017-11-28

  机译： IL-3抑制剂在早期治疗类风湿关节炎中的应用

• 4. IL-3 INHIBITORS IN USE FOR TREATMENT OF RHEUMATOID ARTHRITIS IN AN EARLY STAGE [P] . 欧洲知识产权局专利： EP2367550B1 . 2017-05-31

  机译： IL-3抑制剂在早期治疗类风湿关节炎中的应用

• 5. IL-3 inhibitors in use for treatment of rheumatoid arthritis in an early stage [P] . AU2009321740B2 . 2014-09-18

  机译： IL-3抑制剂在早期用于治疗类风湿关节炎

• 1. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: Observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts [J] . Saedis Saevarsdottir, Sara Wedrén, Maria Seddighzadeh, Arthritis & Rheumatism . 2011,第1期
• 2. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents? [J] . Mark C. Genovese, Arthur Kavanaugh, Michael E. Weinblatt, Arthritis & Rheumatism . 2011,第2期
• 3. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. [J] . Saevarsdottir S, Wedren S, Seddighzadeh M, Arthritis and Rheumatism . 2011,第1期
• 4. Development of TNF-alpha Inhibitor Drugs in Treatment of Rheumatoid Arthritis [C] . Dong Jin-rui, He Ming-hao, Han Mo, Biomedical Engineering and Biotechnology (iCBEB), 2012 International Conference on . 2012
• 5. Multicyclic Grafted Peptides Derived from CD2 Protein to Inhibit Protein-Protein Interaction Between CD2 And CD58 Costimulatorymolecules: Implications in Rheumatoid Arthritis. [D] . Sable, Rushikesh V. 2017
• 6. Use of antidepressants and benzodiazepine-related hypnotics before and after initiation of TNF-α inhibitors or non-biological systemic treatment in patients with rheumatoid arthritis psoriatic arthritis or ankylosing spondylitis [O] . Philip Brenner, Anna Citarella, Louise Wingård, 2020
• 7. THU0171 TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF RHEUMATOID ARTHRITIS – THE RESULTS OF RUSSIAN NATIONAL REGISTER OF PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TOFACITINIB [O] . Inna Gaydukova, V Mazurov, Evgeniy Zhilyaev, 2019

• 1. THERAPEUTIC EFFECTS OF THE INSTANT RHEUMATOID MEDICINAL GRANULES FOR TREATMENT OF ACUTE RHEUMATOID ARTHRITIS - A Report of 34 cases [J] . 寇秋爱 ,房定亚 . 中医杂志：英文版 . 1997,第3期
• 2. Blood glucose changes surrounding initiation of tumor-necrosis factor inhibitors and conventional disease-modifying anti-rheumatic drugs in veterans with rheumatoid arthritis [J] . Patrick R Wood ,Evan Manning ,Joshua F Baker . 世界糖尿病杂志：英文版（电子版） . 2018,第2期
• 3. TNF-α inhibitors and tocilizumab do not influence hepatic steatosis in patients with rheumatoid arthritis [J] . Paola Sessa ,Matteo Nicola Dario Di Minno ,Rosella Tirri . 世界风湿病学杂志 . 2014,第1期
• 4. Protein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/clinical perspectives [J] . Charles J Malemud ,David E Blumenthal . 世界骨科杂志：英文版 . 2014,第4期
• 5. Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: Results of a systematic review [J] . Herma H Fidder ,Maartje MJ Singendonk ,Mike van der Have . 世界胃肠病学杂志：英文版 . 2013,第27期
• 6. 国产依那西普类似物治疗早期活动性类风湿关节炎的药物经济学评价 [C] . HU Zhan-hong ,胡展红 ,SHI Ai-ming . 2016年江苏省药学大会暨第十六届江苏省药师周 . 2016
• 7. 艾拉莫德治疗早期类风湿关节炎6个月的疗效和安全性研究 [A] . 郭伟 . 2019